Trials that use: Log-rank test
New to this method? Read the tutorial →
407 results
- Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC): Complete Statistical AnalysisIndependent statistical analysis of Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Methods Project 4: Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Methods Project 4: Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01867242).
- METROIndependent statistical analysis of Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- MMVAR – Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- MONARCH plusIndependent statistical analysis of A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02763566).
- MORE-CAREIndependent statistical analysis of MOnitoring REsynchronization deviCes and cARdiac patiEnts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00885677).
- MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180634).
- N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure: Complete Statistical AnalysisIndependent statistical analysis of N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00248625).
- Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence…
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.
- NARLALIndependent statistical analysis of Navelbine And Radiotherapy in Locally Advanced Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00887783).
- NATRONIndependent statistical analysis of A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NAVIGATE ESUSIndependent statistical analysis of NAVIGATE ESUS, a randomized phase 3 trial comparing rivaroxaban with aspirin in patients with recent embolic stroke of undetermined source, including time-to-event methods, primary and secondary results, safety,…
- NETTER-1Independent statistical analysis of the phase 3 NETTER-1 trial comparing 177Lu-DOTA0-Tyr3-Octreotate with Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours.
- NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NO16968Independent statistical analysis of NO16968 (NCT00069121), a randomized phase 3 trial of capecitabine plus oxaliplatin versus 5-FU/LV in colorectal cancer, including disease-free survival, relapse-free survival, overall survival, statistical methodology, and interpretation.
- OAKTREEComplete statistical analysis of the randomized phase 3 OAKTREE trial of obeldesivir in nonhospitalized participants with COVID-19, including trial design, endpoints, survival analysis, viral-load analysis, safety, statistical methodology, results, and interpretation.
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- OReOIndependent statistical analysis of A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- PACEComplete statistical analysis of the randomized phase 2 PACE trial evaluating palbociclib-based treatment after CDK and endocrine therapy in metastatic breast cancer, including PFS, response, statistical methodology, safety, and interpretation.
- PACIFICComplete statistical analysis of the PACIFIC phase 3 trial of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer, including primary endpoints, time-to-event methods, secondary analyses, safety,…
- PACIFIC-AMIComplete statistical analysis of PACIFIC-AMI, the randomized phase 2 trial of asundexian versus placebo following acute myocardial infarction, including time-to-event endpoints, hazard ratios, confidence intervals, safety, and statistical interpretation.
- PACIFIC-STROKEComplete statistical analysis of PACIFIC-STROKE, the randomized phase 2 trial of BAY 2433334 in patients following a recent non-cardioembolic ischemic stroke, including endpoint definitions, dose-response analysis, bleeding outcomes, hazard ratios, confidence intervals,…
- PALLASComplete statistical analysis of the PALLAS phase 3 trial of dronedarone versus placebo in patients with permanent atrial fibrillation, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, p-values, and statistical interpretation.
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…
- PERSISTIndependent statistical analysis of Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01358357).
- PIONEER AF-PCIIndependent statistical analysis of A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: primary endpoint…
- PIX-RIndependent statistical analysis of Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are…
- PrE0801Independent statistical analysis of NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PRESIDEIndependent statistical analysis of A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking…
- PREVENT-HDA detailed statistical analysis of the phase 3 PREVENT-HD trial of rivaroxaban versus placebo in medically ill outpatients with acute symptomatic COVID-19 infection, including its time-to-event endpoints, hazard ratio, confidence interval, log-rank…
- PRIORITIIndependent statistical analysis of A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.: primary endpoint results,…
- PROCLAIMIndependent statistical analysis of the PROCLAIM phase 3 trial, including its randomized design, overall survival analysis, progression-free survival, response, relapse patterns, swallowing outcomes, safety, statistical methods, and interpretation.
- PROFILE 1014Independent statistical analysis of PROFILE 1014, evaluating crizotinib versus pemetrexed plus cisplatin or carboplatin in ALK-positive non-squamous lung cancer, with detailed interpretation of progression-free survival, overall survival, response, patient-reported outcomes, and statistical…
- ProspectIndependent statistical analysis of A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer: primary endpoint results, effect estimate with…
- PROTECTIndependent statistical analysis of the randomized phase 3 PROTECT trial of sipuleucel-T in prostate cancer, including its time-to-biochemical-failure endpoints, stratified log-rank analysis, hazard ratio, confidence interval, and statistical interpretation.